All In Biotech

Drugs by condition

Drugs approved for myelofibrosis

Brand-name prescription drugs and biologics whose FDA label lists myelofibrosis as an approved use. Matched on the label phrases: "myelofibrosis".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

5

Still marketed, NDA or BLA

Drug classes

2

Novel drugs

4

New molecular entities and new biologics

In development

12

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for myelofibrosis.

  • Jakafi Xr (Ruxolitinib Phosphate) · Incyte Corp OrphanMay 1, 2026
  • Ojjaara (Momelotinib Dihydrochloride) · Glaxosmithkline NovelOrphanSep 15, 2023
  • Vonjo (Pacritinib Citrate) · Sobi NovelAccelerated approvalPriority reviewOrphanFeb 28, 2022
  • Inrebic (Fedratinib Hydrochloride) · Bristol-Myers NovelPriority reviewOrphanAug 16, 2019
  • Jakafi (Ruxolitinib Phosphate) · Incyte Corp NovelPriority reviewOrphanNov 16, 2011

All approved drugs for myelofibrosis, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Kinase Inhibitor (3)

  • Vonjo Pacritinib Citrate · Sobi · 2022
  • Jakafi Ruxolitinib Phosphate · Incyte Corp · 2011
  • Jakafi Xr Ruxolitinib Phosphate · Incyte Corp · 2026

Class not listed in FDA's data (2)

  • Ojjaara Momelotinib Dihydrochloride · Glaxosmithkline · 2023
  • Inrebic Fedratinib Hydrochloride · Bristol-Myers · 2019

Drugs in development for myelofibrosis

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • ElriterceptTAK-226, KER-050Phase 36 trials

    Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia

  • BomedemstatMK-3543, IMG-7289Phase 35 trials

    Merck & Co. · Polycythemia Vera, Essential Thrombocythemia, Thrombocythemia, Essential

  • RovadicitinibTQ05105Phase 35 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Graft Versus Host Disease, Myelofibrosis, Graft-versus-host Disease

  • KRT-232NavtemadlinPhase 34 trials

    Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma

  • PelabresibDAK539, CPI-0610Phase 34 trials

    Novartis · Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis (PMF)

  • roginolisibIOA-244Phase 23 trials

    iOnctura · Myelofibrosis (MF), Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC

  • BMS-986158Phase 22 trials

    Bristol Myers Squibb · Myelofibrosis, Multiple Myeloma

  • DISC-0974Phase 22 trials

    Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia

  • amsulostatPXS-5505Phase 21 trial

    Syntara · Myelofibrosis, Primary Myelofibrosis (PMF), Post- Essential Thrombocythemia Myelofibrosis

  • GB2064Phase 21 trial

    Galecto Biotech AB · Myelofibrosis

  • TL-895Phase 21 trial

    Telios Pharma, Inc. · Myelofibrosis, Primary Myelofibrosis, Post-PV MF

  • TQB3617Phase 21 trial

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Myelofibrosis

More on myelofibrosis: recruiting trials · published research

Related in hematology and blood cancers: Multiple myeloma · Acute myeloid leukemia · Chronic lymphocytic leukemia · Acute lymphoblastic leukemia · Chronic myeloid leukemia · Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Myelodysplastic syndromes · Sickle cell disease · Hemophilia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.